We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aspira Womans Health Inc | NASDAQ:AWH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 1.02% | 2.98 | 2.74 | 3.74 | 3.06 | 2.8169 | 2.95 | 15,037 | 23:51:48 |
“We are very pleased with the growth in positive medical policy coverage with the addition of AIM Specialty Health’s Clinical Appropriateness Guidelines and Medicaid coverage and credentialing for OVA1. In addition, in spite of renewed COVID-19 restrictions we were able to grow in specific markets,” indicated Valerie Palmieri, Aspira’s Chief Executive Officer. “We are also making positive progress on our product collaboration with the Dana Farber Cancer Institute with the successful completion of the Phase 1 of our proof of concept study relating to our OvaInherit trial. We had continued positive dialogue with the Food and Drug Administration regarding our planned EndoCheck product and expect resolution on our optimal regulatory path forward for Endocheck by the end of the year.”
Recent Corporate Highlights
Financial Highlights
Highlights of Third Quarter 2021 vs. Third Quarter 2020:
Highlights of Third Quarter 2021 vs. Second Quarter 2021:
Conference Call and Webcast
Aspira will host a call today at 8:30 a.m. Eastern Time to discuss results followed by a question-and-answer period.
Domestic: | 877-407-4018 |
International: | 201-689-8471 |
Conference ID: | 13724440 |
Webcast: | https://78449.themediaframe.com/dataconf/productusers/vvdb/mediaframe/47156/indexl.html |
About Aspira Women’s Health Inc.Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus™ combines our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX™ testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is working to deliver a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVASight™, which we are rebranding as OvaWatch™, and EndoCheck™. Visit our website for more information at www.aspirawh.com.
Forward-Looking StatementsThis press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations with respect to studies relating to OvaInherit and plans with respect to OvaSight/OvaWatch, including its rebranding, scientific and market review and launch dates. Forward-looking statements involve a number of risks and uncertainties. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those described in the section entitled “Risk Factors” in Aspira’s Annual Report on Form 10-K for the year ended December 31, 2020, as supplemented by the section entitled “Risk Factors” in Aspira’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. The events and circumstances reflected in Aspira’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Aspira expressly disclaims any obligation to update, amend or clarify any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLCTel: 617-535-7742
Aspira Women’s Health Inc. | ||||||||
Condensed Consolidated Balance Sheets | ||||||||
(Amounts in Thousands, Except Share and Par Value Amounts) | ||||||||
(Unaudited) | ||||||||
September 30,2021 | December 31,2020 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 44,870 | $ | 16,631 | ||||
Restricted cash | 250 | - | ||||||
Accounts receivable | 1,103 | 865 | ||||||
Prepaid expenses and other current assets | 828 | 1,077 | ||||||
Inventories | 137 | 30 | ||||||
Total current assets | 47,188 | 18,603 | ||||||
Property and equipment, net | 498 | 583 | ||||||
Right-of-use assets | 361 | 406 | ||||||
Other assets | - | 13 | ||||||
Total assets | $ | 48,047 | $ | 19,605 | ||||
Liabilities and Stockholders’ Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,155 | $ | 1,103 | ||||
Accrued liabilities | 4,998 | 3,618 | ||||||
Current portion of long-term debt | 200 | 645 | ||||||
Short-term debt | - | 611 | ||||||
Lease liability | 56 | 23 | ||||||
Total current liabilities | 6,409 | 6,000 | ||||||
Non-current liabilities: | ||||||||
Long-term debt | 2,768 | 3,477 | ||||||
Lease liability | 366 | 409 | ||||||
Total liabilities | 9,543 | 9,886 | ||||||
Commitments and contingencies | ||||||||
Stockholders’ equity: | ||||||||
Common stock, par value $0.001 per share, 150,000,000 shares authorized at September 30, 2021 and December 31, 2020; 112,100,049 and 104,619,876 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively | 112 | 105 | ||||||
Additional paid-in capital | 501,159 | 449,680 | ||||||
Accumulated deficit | (462,767 | ) | (440,066 | ) | ||||
Total stockholders’ equity | 38,504 | 9,719 | ||||||
Total liabilities and stockholders’ equity | $ | 48,047 | $ | 19,605 |
Aspira Women’s Health Inc. | ||||||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||||||
(Amounts in Thousands, Except Share and Per Share Amounts) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Revenue: | ||||||||||||||||
Product | $ | 1,614 | $ | 1,217 | $ | 4,748 | $ | 3,128 | ||||||||
Genetics | 49 | 22 | 208 | 64 | ||||||||||||
Service | 3 | - | 5 | 13 | ||||||||||||
Total revenue | 1,666 | 1,239 | 4,961 | 3,205 | ||||||||||||
Cost of revenue(1): | ||||||||||||||||
Product | 694 | 670 | 2,167 | 1,793 | ||||||||||||
Genetics | 223 | 133 | 746 | 394 | ||||||||||||
Service | - | 4 | - | 13 | ||||||||||||
Total cost of revenue | 917 | 807 | 2,913 | 2,200 | ||||||||||||
Gross profit | 749 | 432 | 2,048 | 1,005 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development(2) | 1,518 | 595 | 3,861 | 1,370 | ||||||||||||
Sales and marketing(3) | 5,083 | 2,152 | 12,209 | 6,000 | ||||||||||||
General and administrative(4) | 3,839 | 1,966 | 9,627 | 5,542 | ||||||||||||
Total operating expenses | 10,440 | 4,713 | 25,697 | 12,912 | ||||||||||||
Loss from operations | (9,691 | ) | (4,281 | ) | (23,649 | ) | (11,907 | ) | ||||||||
Interest income (expense), net | (14 | ) | 5 | (35 | ) | 14 | ||||||||||
Other income (expense), net | (2 | ) | (11 | ) | 983 | 69 | ||||||||||
Net loss | $ | (9,707 | ) | $ | (4,287 | ) | $ | (22,701 | ) | $ | (11,824 | ) | ||||
Net loss per share - basic and diluted | $ | (0.09 | ) | $ | (0.04 | ) | $ | (0.20 | ) | $ | (0.12 | ) | ||||
Weighted average common shares used to compute basic and diluted net loss per common share | 112,077,133 | 103,200,612 | 110,904,824 | 99,555,194 | ||||||||||||
Non-cash stock-based compensation expense included in cost of revenue and operating expenses: | ||||||||||||||||
(1) Cost of revenue | $ | 50 | $ | 20 | $ | 137 | $ | 73 | ||||||||
(2) Research and development | 115 | 16 | 235 | 17 | ||||||||||||
(3) Sales and marketing | 367 | 31 | 843 | 116 | ||||||||||||
(4) General and administrative | 646 | 343 | 1,734 | 915 |
1 Year Aspira Womans Health Chart |
1 Month Aspira Womans Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions